Chugai OTC Stock Executives

CHGCF -  USA Stock  

USD 33.22  0.00  0.00%

Chugai Pharmaceutical employes about 7.6 K people. The company is managed by 41 executives with total tenure of roughly 212 years, averaging almost 5.0 years of service per executive having 184.27 employees per reported executive. Evaluation of Chugai Pharmaceutical management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Chugai Pharmaceutical future performance.
Continue to Trending Equities.

Chugai Insiders 

 
Refresh
  Osamu Nagayama  Chairman
Chairman and CEO
  Motoo Ueno  Chairman
Vice Chairman of the Board, Representative Director
  Tatsuro Kosaka  President
President, COO and Representative Director

Chugai Pharmaceutical Management Team Effectiveness

Chugai Pharmaceutical has return on total asset (ROA) of 17.91 % which means that it generated profit of $17.91 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 25.44 %, meaning that it generated $25.44 on every $100 dollars invested by stockholders. Chugai Pharmaceutical management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Chugai Pharmaceutical Workforce Comparison

Chugai Pharmaceutical is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is currently estimated at about 404,569. Chugai Pharmaceutical claims roughly 7,555 in number of employees contributing just under 2% to equities under Drug Manufacturers—General industry.

Chugai Pharmaceutical Profit Margins

The company has Profit Margin (PM) of 28.88 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 40.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.4.

Chugai Pharmaceutical Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Chugai Pharmaceutical Price Series Summation is a cross summation of Chugai Pharmaceutical price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Chugai Pharmaceutical Notable Stakeholders

A Chugai Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Chugai Pharmaceutical often face trade-offs trying to please all of them. Chugai Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Chugai Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Osamu Nagayama - Chairman and CEOProfile
Motoo Ueno - Vice Chairman of the Board, Representative DirectorProfile
Tatsuro Kosaka - President, COO and Representative DirectorProfile
Masayuki Oku - Independent DirectorProfile
Franz Humer - Independent DirectorProfile
Sophie KornowskiBonnet - Independent DirectorProfile
Yasuo Ikeda - Independent DirectorProfile
Yoshiyuki Yano - Executive Officer, Director of Human ResourcesProfile
William Anderson - DirectorProfile
Toshihiko Komori - Executive Officer, Assistant Manager of Project & Life Cycle Management Unit, Director of R&D PortfolioProfile
Mamoru Togashi - Executive Officer, Director of Human Resources, Senior Manager of Human Resources DivisionProfile
James Sabry - DirectorProfile
Daniel ODay - Independent DirectorProfile
Minoru Watanabe - Executive Officer, Director of Business PlanningProfile
Shinji Hidaka - Executive Officer, Deputy Chief Director of Sales, Manager of Primary UnitProfile
Tetsuya Yamaguchi - Executive Officer, Director of Business DevelopmentProfile
Hitoshi Kuboniwa - Executive Officer, Chief Director of Pharmaceutics ProducingProfile
Masaaki Tohaya - Managing Executive Officer, Chief Director of SalesProfile
Tsunanori Sato - Executive Officer, Chief Director of SalesProfile
Koichi Nishikawa - Executive Officer, Deputy Chief Director of Sales, Director of Marketing PlanningProfile
Osamu Okuda - Executive Officer, Director of Business PlanningProfile
Yoshiaki Ohashi - Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management UnitProfile
Christoph Franz - DirectorProfile
Shinya Unno - Managing Executive Officer, Director of Business PlanningProfile
Hisanori Takanashi - Executive Officer, Chief Director of Clinical DevelopmentProfile
Hiroshi Murata - Executive Officer, Chief Director of Pharmaceutical TechnologyProfile
Yoichiro Ichimaru - Independent DirectorProfile
Yoshio Itaya - CFO, Executive VP, General Manager of Fin. Supervisory Division and DirectorProfile
Yasushi Ito - Executive Officer, Chief Director of Clinical DevelopmentProfile
Mitsuru Kikuchi - Managing Executive Officer, Director of External InvestigationProfile
Toshiaki Itagaki - VP and General Manager of Fin. and Accounting DepartmentProfile
Junichi Ebihara - VP and General Manager of Legal DepartmentProfile
Hisafumi Okabe - VP and General Manager of Research DivisionProfile
Harunori Yamazaki - Manager of Accounting Group in Finance & Accounting UnitProfile
Yutaka Tanaka - Managing Executive Officer, Manager of Life Circle Management and Marketing UnitProfile
Tadahiko Sato - Executive Officer, Senior Manager of Tokyo 1st OfficeProfile
Yoko Kitagawa - Manager of Consolidated Financial Group in Finance & Accounting UnitProfile
Hiroyuki Matsumoto - Executive Officer, Senior Manager of South Kanto Office in Main Sales UnitProfile
Satoko Shisai - Executive Officer, Senior Manager of ITProfile
Keiji Kono - Executive Officer, Senior Manager of IT DivisionProfile
Susumu Kato - Executive Officer, Senior Manager of Tokyo First OfficeProfile

About Chugai Pharmaceutical Management Performance

The success or failure of an entity such as Chugai Pharmaceutical often depends on how effective the management is. Chugai Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chugai management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chugai management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. Chugai Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 7555 people.
The data published in Chugai Pharmaceutical's official financial statements usually reflect Chugai Pharmaceutical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Chugai Pharmaceutical. For example, before you start analyzing numbers published by Chugai accountants, it's critical to develop an understanding of what Chugai Pharmaceutical's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Chugai Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chugai Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Chugai Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chugai Pharmaceutical. Please utilize our Beneish M Score to check the likelihood of Chugai Pharmaceutical's management to manipulate its earnings.

Chugai Pharmaceutical Workforce Analysis

Traditionally, organizations such as Chugai Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Chugai Pharmaceutical within its industry.

Chugai Pharmaceutical Manpower Efficiency

Return on Chugai Pharmaceutical Manpower

Revenue Per Employee117.5 M
Revenue Per Executive21.7 B
Net Income Per Employee33.9 M
Net Income Per Executive6.3 B
Working Capital Per Employee57.6 M
Working Capital Per Executive10.6 B
Continue to Trending Equities. Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Chugai OTC Stock analysis

When running Chugai Pharmaceutical price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Chugai Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chugai Pharmaceutical. If investors know Chugai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chugai Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chugai Pharmaceutical is measured differently than its book value, which is the value of Chugai that is recorded on the company's balance sheet. Investors also form their own opinion of Chugai Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Chugai Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chugai Pharmaceutical's market value can be influenced by many factors that don't directly affect Chugai Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chugai Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine Chugai Pharmaceutical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chugai Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.